AOD-9604 for Health & Longevity
Evidence Review created on 10/30/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: AOD9604, Anti-Obesity Drug 9604, LAT8881, Tyr-hGH177-191, HGH Fragment 176-191
Motivation
AOD-9604 is a small, lab-made piece of human growth hormone. It copies the short tail end of the hormone that appears to control fat breakdown, while leaving out the parts that drive growth and raise blood sugar. That design is the source of its appeal: the promise of growth hormone’s effect on body fat without the hormone’s best-known drawbacks.
The compound was developed in Australia as an oral weight-loss drug and was tested in a series of company-run human studies in the early 2000s. It later resurfaced as an injectable “research peptide” sold online and through peptide clinics, promoted for fat loss and, more recently, for joint cartilage repair. It has also drawn attention from drug regulators and sports anti-doping bodies.
This review examines what the human, animal and laboratory evidence shows about AOD-9604’s benefits and risks for health-focused adults, how it is used in practice, which sources of bias shape the evidence base, and what regulators have said about it.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists overview content that discusses AOD-9604 by name in depth.
-
#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field - Peter Attia
A physician’s framework applied to gray-market peptides, with a dedicated AOD-9604 section weighing the sponsor safety trials against the failed efficacy trial and its repositioning as LAT8881.
-
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans - Stier et al., 2013
The only full report of six sponsor-funded trials in about 900 adults, covering adverse events, glucose handling and growth-factor levels; its authors include a sponsor consultant and a shareholder.
-
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance - Mendias & Awan, 2026
A sports-medicine narrative review profiling AOD-9604 alongside other gray-market peptides, contrasting favorable animal findings with scarce human safety data and unapproved regulatory status.
-
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration - Dominikowski et al., 2026
An endocrinology review of the growth hormone–insulin-like growth factor 1 (GH-IGF1) pathway that rates AOD-9604’s human evidence as short-term trials with limited interpretable signals.
-
AOD-9604: Benefits, Dosage & Risks - Nick Urban
A biohacking-oriented evidence report that documents the abandoned human obesity program, the anecdotal subcutaneous (under-the-skin) dose range and gray-market product risk, scoring AOD-9604 low.
No directly relevant content on AOD-9604 was found from Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; web searches and each site’s own search returned nothing on the compound.
Grokipedia
A concise overview of structure, development history, the 2007 end of the obesity program and current regulatory status; note that it calls AOD-9604 a growth hormone receptor agonist, which binding studies contradict.
Examine
No Examine article on AOD-9604 exists.
ConsumerLab
No ConsumerLab article on AOD-9604 exists.
Systematic Reviews
This section lists the one systematic review that covers an AOD-9604 trial.
-
Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials - Huerta et al., 2023
Reviews 18 randomized trials for nerve pain after shingles, including the oral LAT8881 (AOD-9604) trial, classed as a first-in-class pain drug; weight is not addressed.
No systematic review or meta-analysis covers AOD-9604’s claimed fat-loss effect or its principal risks (adverse events, product safety); both sides are unrepresented.
Mechanism of Action
AOD-9604 is a synthetic 16-amino-acid peptide: residues 177–191 of human growth hormone (hGH) plus an added front-end tyrosine (Stier 2013), closed by a disulfide bridge (a sulfur–sulfur loop) (Ogru 2000). Mechanistic data come mainly from its inventor, Monash University, and human data from its developers, a financial conflict of interest.
- Fat-cell action: In obese mice it raised markers of lipolysis (breakdown of stored fat) and fat oxidation (fat burning) (Heffernan 2001). The unmodified 177–191 sequence blocked lipogenesis (new fat synthesis) without lipolysis in rat fat (Wu 1993), leaving the dominant action unsettled.
- Beta-3 adrenergic link: It raised expression of the beta-3 adrenergic receptor (a fat-burning adrenaline receptor); mice lacking it lost the chronic weight effect but kept an acute rise in fat oxidation (Heffernan 2001).
- Selectivity and target: It does not bind the growth hormone receptor (Heffernan 2001) and left IGF-1 (insulin-like growth factor 1, growth hormone’s main growth signal) unchanged (Stier 2013). A developer-co-authored study found its binding target, LanCL1 (lanthionine synthetase C-like protein 1, a protein that mediates nerve-pain sensitization) (Spanswick 2026).
- Competing claims: One review’s abstract claims IGF-1 activation, contradicted by its own text (Rahman 2026); early tail fragments raised blood glucose in animals (Wade 1979).
- Pharmacokinetics: Human intravenous levels peaked within 5 minutes (NCT05298306); human half-life is unpublished. In pigs, intravenous half-life was 3 minutes; in rats it reached pancreas, thyroid, liver and kidney (Moré 2014). Serum peptidases (protein-cutting enzymes) fragment it, one fragment outlasting the parent (Cox 2015); cytochrome P450 (drug-processing liver enzymes) is unstudied.
Historical Context & Evolution
AOD-9604 grew out of Monash University work on growth hormone fragments, showing that different segments carry different metabolic actions; tail-end fragments were first studied for blood-sugar-raising activity (Wade 1979). In the 1990s, the segment spanning residues 177–191 was found to block fat synthesis in fat cells (Wu 1993), and a stabilized version reduced weight gain in obese rats when given by mouth (Ng 2000).
Its original intended use was as an oral obesity drug. Metabolic Pharmaceuticals ran six placebo-controlled trials between 2001 and 2006 (Stier 2013). A 12-week capsule trial reported more weight loss than placebo, but a larger 24-week tablet trial in less obese adults did not, and the obesity program was terminated in 2007, as summarized in a review (Misra 2013); the reason is untested. The negative result was disclosed in a 2007 stock-exchange announcement rather than a journal article, as a later review notes (Dominikowski 2026), so outsiders cannot examine dose groups or confidence limits.
After 2007 the peptide was repositioned toward food-ingredient use, backed by an expert-panel safety determination that the sponsor’s safety report describes (Stier 2013), and toward osteoarthritis cartilage repair, supported by a rabbit study (Kwon 2015). Health-optimization interest came from this “fat loss without growth hormone side effects” narrative, injected rather than taken orally. The World Anti-Doping Agency (WADA) prohibits it (WADA Prohibited List), and the US Food and Drug Administration (FDA) reviewed it for compounding at a 2024 meeting of its Pharmacy Compounding Advisory Committee (PCAC) (FDA PCAC December 4, 2024 meeting).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the only human efficacy data are obesity trials run by a single sponsor, and the larger of them was negative.
Medium 🟩 🟩
No benefit reaches Medium: the one positive human trial is reported only secondhand and is outweighed by the sponsor’s larger negative trial, while the remaining outcome data come from rodents and rabbits.
Low 🟩
Weight Loss in Obesity ⚠️ Conflicted
Obese mice given AOD-9604 gained less weight and burned more fat (Heffernan 2001). A review reports the sponsor’s 12-week oral trial showed weight loss but its 24-week trial in 536 adults did not (Misra 2013). Injected use, today’s route, is untested. Net: the larger negative trial outweighs the positive one.
Magnitude: A review reports 2.6 kg weight loss with 1 mg daily versus 0.8 kg with placebo at 12 weeks, for each group and not compared between groups; the 24-week trial reported no significant difference and no figure (Misra 2013).
Improved Glucose Tolerance ⚠️ Conflicted
The sponsor reports that participants with impaired glucose tolerance (above-normal glucose after a sugar drink) progressed to diabetes less often on AOD-9604 than placebo (Stier 2013); obese rats kept normal insulin sensitivity (Ng 2000). Yet glucose-tolerance tests changed insignificantly in both long trials. Net: no confirmed glucose benefit.
Magnitude: At 24 weeks, change in pre-load glucose differed from placebo by −0.03, 0.02 and 0.06 units at 0.25, 0.5 and 1 mg, none significant; the diabetes-progression observation was reported without figures (Stier 2013).
Speculative 🟨
Cartilage Repair in Osteoarthritis
In rabbits with induced knee osteoarthritis, weekly AOD-9604 joint injections improved cartilage scores and shortened lameness, more so with hyaluronic acid (a joint lubricant) (Kwon 2015). No human study exists; the basis is animal only.
Benefit-Modifying Factors
- Genetic polymorphisms: No gene variant is known to modify AOD-9604’s effects; no pharmacogenetic (gene-guided drug response) study exists.
- Baseline biomarkers: Efficacy trials enrolled obese adults with a body mass index (BMI, weight relative to height) of 30–35 or more (Stier 2013); any effect in lean or mildly overweight people is untested. The impaired-glucose-tolerance observation applies only to that subgroup.
- Sex: The first four trials enrolled only men; the two longer trials enrolled 46–56% women but reported no sex-specific efficacy results (Stier 2013).
- Pre-existing conditions: Obesity is the only condition tested in humans. Osteoarthritis benefit rests on a rabbit model (Kwon 2015); people with type 2 diabetes were not studied.
- Age: The 12-week trial enrolled adults aged 30–65 (Stier 2013); no efficacy results are reported for people over 65, in whom muscle preservation during weight loss matters more.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: recorded human harms come from one sponsor’s trial program, with no trials from a second independent research group.
Medium 🟥 🟥
No risk reaches Medium: the controlled human harm signals come from small single-sponsor trials and are either contradicted by larger placebo-controlled trials or unreplicated.
Low 🟥
Headache, Gastrointestinal Upset and Infusion-Related Euphoria ⚠️ Conflicted
In a 7-day sponsor trial, 54 mg oral doses brought more headache, diarrhea and flatulence; intravenous infusion brought euphoria judged possibly related (Stier 2013). A review lists headache (Dominikowski 2026). A larger 4-week trial of 60 mg daily found no excess headache (NCT03865953). Net: high-dose effects are unconfirmed.
Magnitude: Headache in 2 of 51 participants on 60 mg daily versus 4 of 51 on placebo (crossover trial) (NCT03865953); euphoria in 5 of 23 participants during AOD-9604 infusion periods versus none during placebo periods, not statistically tested; the 54 mg excess was reported without rates, and one serious diarrhea at 54 mg was judged possibly related versus no serious event during placebo periods, although the abstract reports no related serious event (Stier 2013).
Growth-Hormone-Like Effects on Glucose and IGF-1 ⚠️ Conflicted
Growth hormone raises glucose and IGF-1, and early synthetic tail fragments raised glucose in animals (Wade 1979). In the sponsor’s placebo-controlled trials, oral AOD-9604 for up to 24 weeks changed neither glucose tolerance nor IGF-1 (Stier 2013). Net: the trials do not support this concern.
Magnitude: At 24 weeks, change in pre-load glucose differed from placebo by −0.03, 0.02 and 0.06 units at 0.25, 0.5 and 1 mg (none significant); IGF-1 showed no difference between groups (P = 0.76, where P is the probability of a difference this large arising by chance) (Stier 2013).
Cancer Diagnoses in a 12-Week Trial ⚠️ Conflicted
In the sponsor’s 12-week trial, five AOD-9604 recipients had serious adverse events (four cancers, one lipoma, a benign fatty lump) versus none on placebo (Stier 2013). Its larger 24-week trial found serious events similar across groups. Reviews call growth-promoting risk unproven (Dominikowski 2026). Net: an unreplicated signal of unclear cause.
Magnitude: Five participants across the five AOD-9604 groups (50 per group) versus none in the placebo group (50) had a serious adverse event, all cancers or a lipoma, not statistically tested; in the 24-week trial 18 of 502 participants (3.6%) had any serious event: 8 of 125 on placebo versus 3 of 127, 1 of 125 and 6 of 125 at 0.25, 0.5 and 1 mg (Stier 2013).
Product Identity, Purity and Sterility
AOD-9604 is sold mainly as an unregulated research chemical, so content and sterility are unverified. Belgian authorities identified AOD-9604 in unknown seized preparations (Vanhee 2014), and a third of black-market performance drugs seized in France were counterfeit (Fabresse 2021). The data are indirect: mostly other drugs, not AOD-9604.
Magnitude: 24 of 75 seized pharmaceuticals were counterfeit and 25 of 75 substandard, mostly anabolic steroids rather than AOD-9604; no control group (Fabresse 2021).
Serious Adverse Events Reported to FDA
FDA states it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear (FDA compounding safety list). The events are not described publicly. Reviews note that harms from gray-market peptides are poorly reported (Hailu 2026), so their frequency is unknown.
Magnitude: Not quantified in available studies. FDA’s listing gives no case count, event type or comparison group, and no case report has been published.
Speculative 🟨
Immune Reactions to Injected Products
FDA flags possible immunogenicity (an immune response against the peptide) and impurities for some routes (FDA compounding safety list). Oral trials found no antibodies; injection lacks human data. The basis is mechanistic only.
Risk-Modifying Factors
- Genetic polymorphisms: No variant is known to alter risk. As a peptide broken into fragments in serum (Cox 2015), it is not expected to depend on CYP2D6 or CYP3A4 (variable liver enzymes that metabolize many drugs), so common drug-metabolism genotypes are unlikely to matter.
- Baseline biomarkers: A high baseline IGF-1 or impaired glucose tolerance would obscure interpretation, because trial reassurance on glucose and IGF-1 covers oral dosing only (Stier 2013).
- Sex: Men dominated early trials; the longer trials included women without sex-specific safety reporting (Stier 2013). Pregnancy was not studied.
- Pre-existing conditions: A personal history of cancer raises the stakes of the unresolved serious-event signal. Weakened immunity raises the consequences of a non-sterile injection.
- Age: Later pain trials enrolled adults up to 75 without age-specific safety reporting (NCT03865953); older adults have higher background cancer rates, which complicates attribution of any new diagnosis.
- Dose and route: At 54 mg orally, headache, diarrhea and flatulence were more frequent; intravenous infusion produced mild or moderate euphoria in 5 of 23 participants versus none on placebo (Stier 2013).
Key Interactions & Contraindications
Documented interactions:
- None identified
Theoretical interactions (inferred from mechanism, not studied in humans):
- Growth hormone and its secretagogues (drugs that trigger the body’s own growth hormone release; e.g., somatropin, CJC-1295, ipamorelin, tesamorelin): often stacked; they raise IGF-1 and glucose, so a rise cannot be attributed. Mitigation: IGF-1 and fasting glucose checks before each added agent.
- Beta-blockers (heart drugs that block adrenaline receptors; e.g., propranolol, metoprolol): inferred from AOD-9604’s beta-adrenergic-linked lipolysis in mice; blockade may blunt any fat-loss effect.
- GLP-1 receptor agonists (drugs that mimic a gut hormone to reduce appetite; e.g., semaglutide, tirzepatide): additive energy deficit; consequence is faster weight loss with greater lean-mass loss risk. Mitigation: adequate protein and resistance training.
- Over-the-counter sympathomimetics (adrenaline-like stimulants; e.g., pseudoephedrine) and caffeine: additive adrenergic stimulation of fat breakdown; consequence is raised heart rate and blood pressure from the stimulant. Mitigation: lower stimulant doses.
- Lipolytic supplements (synephrine, yohimbine, green tea extract): additive fat-mobilizing and stimulant effects; consequence is palpitations or anxiety. Mitigation: one new agent at a time.
- Intra-articular (injected into the joint) hyaluronic acid: additive cartilage effect in rabbits (Kwon 2015); consequence in humans unknown, with joint-infection risk from repeated injections. Mitigation: sterile, image-guided injection by a clinician.
Populations who should avoid AOD-9604:
- Competitive athletes subject to anti-doping testing: AOD-9604 is prohibited at all times under WADA category S2 (WADA Prohibited List).
- Pregnancy and breastfeeding: inferred from the absence of any reproductive or lactation data and the peptide’s growth hormone origin; no human data.
- Active cancer or recent cancer history: inferred from the growth hormone origin and the unexplained cancer cluster in one trial (Stier 2013); causality is unproven.
- Children and adolescents: inferred from the absence of any pediatric data and growth-axis concerns; no human data.
- Immunocompromised people using unverified injectables: inferred from FDA’s immunogenicity and impurity concerns (FDA compounding safety list) and infection risk from non-sterile injections; no AOD-9604-specific data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Verified product: Lots with certificates of analysis showing mass-spectrometry identity, purity of at least 98%, and endotoxin (bacterial toxin) and sterility results; this mitigates counterfeit, contaminated or mislabeled product.
- Aseptic (germ-free) injection technique: Single-use needles, alcohol swabs, rotated sites, and refrigerated reconstituted vials used within about four weeks; this mitigates injection-site infection.
- Glucose and IGF-1 checks: Testing at baseline and after 8–12 weeks; a rise above the age-specific IGF-1 range or in fasting glucose prompts stopping, as it suggests a contaminant or a stacked growth-hormone agent.
- Cancer screening before starting: Up-to-date age-appropriate skin and breast screening, with prompt reporting of new skin lesions; this addresses the unresolved cancer signal.
- Lower oral doses: Headache and gastrointestinal effects clustered at 54 mg orally (Stier 2013); trial doses of 0.25–1 mg showed placebo-like tolerability.
- Stopping at signs of an immune reaction: Hives, facial swelling or breathing difficulty after injection prompt stopping and urgent care; this mitigates immunogenicity.
Therapeutic Protocol
Other parameters without a citation (timing, cycling, titration) reflect common practice.
- Oral trial regimen: Metabolic Pharmaceuticals tested 0.25, 0.5 or 1 mg oral tablets once daily for 24 weeks, and 1–30 mg capsules for 12 weeks (Stier 2013).
- Subcutaneous regimen: Gray-market users commonly inject about 300 µg once daily, fasted, an anecdotal figure (Outliyr AOD-9604 report); forums cited by a review report 250–500 µg daily in 2–3 injections (Dominikowski 2026); neither is trial-tested.
- Joint-focused regimen: A review notes regenerative osteoarthritis protocols combining AOD-9604 with hyaluronic acid or platelet-rich plasma (a concentrate of the person’s own platelets) (Rahman 2026); the only tested joint dose is 0.25 mg weekly in rabbit knees (Kwon 2015).
- Time of day: Common practice is a morning dose on an empty stomach, before exercise or breakfast; no study compared timings.
- Half-life: No human half-life is published; in serum the intact peptide is less stable than one of its fragments (Cox 2015), consistent with short-lived exposure after each dose.
- Single or split dosing: All trials used one daily dose (Stier 2013); forum protocols cited by a review split injected doses 2–3 times daily (Dominikowski 2026); split dosing is untested in trials.
- Genetic polymorphisms: No genotype is known to change the dose; none was studied.
- Sex: Trials gave men and women the same doses and reported no sex-specific dosing differences (Stier 2013).
- Age: Pain trials enrolled adults up to 75 but reported no age-specific dosing (NCT03865953); older users have no tested regimen.
- Baseline biomarkers: Oral doses were tested only at a BMI of 30 or more; one intravenous safety study enrolled BMI 24–30 (Stier 2013); baseline IGF-1 and fasting glucose identify people whose later readings would be uninterpretable.
- Pre-existing conditions: Joint-focused use rests on osteoarthritis models; weight-focused use on obesity trials. Diabetes, kidney and liver disease were not studied.
Discontinuation & Cycling
- Short-term intent: Trials lasted at most 24 weeks (Stier 2013); AOD-9604 is used in time-limited courses, and no lifelong-use data exist.
- Withdrawal effects: None were reported during trial follow-up of up to 30 days (Stier 2013), though withdrawal symptoms were not specifically assessed.
- Tapering: Not applicable; no dependence or rebound mechanism is known, and trials stopped abruptly.
- Cycling: Common practice runs 8–12 weeks on and 4 weeks off; no evidence shows tolerance or that cycling preserves any effect.
- Weight after stopping: No study has followed weight or body fat after discontinuation.
Sourcing and Quality
- No regulated product: No approved or pharmaceutical-grade AOD-9604 is sold; the trial material was made under current good manufacturing practice (cGMP, regulated production standards) by PolyPeptide Laboratories (Stier 2013).
- US compounding: FDA lists AOD-9604 among nominated-then-withdrawn compounding substances with immunogenicity and impurity concerns (FDA compounding safety list); no brand or compounding pharmacy can be named as vetted.
- Identity testing: The trial peptide has the sequence YLRIVQCRSVEGSCGF (Stier 2013); independent mass spectrometry checks identity against it, and high-performance liquid chromatography (HPLC, a purity test) checks purity.
- Sterility and endotoxin: Injectable vials need sterility and endotoxin testing per lot; research-chemical labels usually lack both.
- Name confusion: Products labeled “HGH Fragment 176-191” may differ from the trial peptide; sequence verification distinguishes them.
- Formulation: Sold as freeze-dried powder reconstituted with bacteriostatic water (sterile water with a preservative) and refrigerated; the trial-era oral tablets are not available.
Practical Considerations
- Time to effect: Trials assessed weight at 12 and 24 weeks; no human data show when, or whether, an effect appears with injected use.
- Common pitfalls: Expecting weight loss comparable to modern appetite-suppressing drugs, confusing AOD-9604 with growth hormone, stacking several peptides so that effects and harms cannot be attributed, and buying untested vials.
- US regulatory status: Not an approved drug; FDA lists safety concerns (FDA compounding safety list) and reviewed it for obesity in 2024 (FDA PCAC December 4, 2024 meeting); it was absent from the July 2026 peptide review (FDA PCAC July 23–24, 2026 meeting).
- Food-ingredient claim: The sponsor reports a GRAS (generally recognized as safe) determination by an expert panel for food use (Stier 2013); this is not an FDA drug approval.
- Anti-doping: Prohibited at all times in sport (WADA Prohibited List).
- Funding incentives: With the obesity program abandoned and no insurer paying for it, no manufacturer or payer has an incentive to fund new trials, which helps explain why evidence remains thin.
- Cost and accessibility: Gray-market vials are inexpensive relative to approved weight-loss drugs; access is easy, but verified quality is not.
Interaction with Foundational Habits
- Sleep: None known. No trial measured sleep; because AOD-9604 left IGF-1 unchanged in trials (Stier 2013), it is not expected to alter the sleep-linked growth hormone pulse. Late-evening dosing has no rationale.
- Nutrition: Indirect. Any fat-loss effect still depends on an energy deficit, since the developers report no effect on appetite in animals (Stier 2013). Common practice doses before breakfast; adequate protein limits lean-mass loss. No nutrient depletion is known.
- Exercise: Potentiating, hypothesized. Fatty acids released by lipolysis must be burned to reduce fat; aerobic exercise raises fat oxidation, so pairing doses with training is plausible but untested. No effect on muscle growth is expected.
- Stress management: None known. Cortisol was not measured in trials, and no stress-related adverse effects were reported; stimulant co-use, not AOD-9604, is the more likely source of restlessness.
Monitoring Protocol & Defining Success
Baseline testing before starting includes body weight, waist circumference and, where available, a body-composition scan, plus fasting glucose, glycated hemoglobin (a 3-month average blood-sugar marker) and IGF-1. These establish a personal reference point, because the main safety question is whether glucose or IGF-1 shift, and the main efficacy question is whether fat mass falls beyond what diet and training achieve alone. Up-to-date age-appropriate cancer screening is part of the baseline.
Ongoing monitoring follows this cadence: weight and waist every 2 weeks; fasting glucose, glycated hemoglobin and IGF-1 at 8–12 weeks and at the end of each course; body composition at the end of each 12-week course. A course without measurable fat loss by 12 weeks counts as non-response, matching the trials’ first assessment point.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Body weight and waist circumference | No established target; track change from own baseline | Expected to change: fat loss is the claimed effect | Same scale, morning, after voiding, before eating; waist measured at the navel |
| Body fat mass (DEXA) | No established target; track change from own baseline | Expected to change: distinguishes fat loss from lean-mass loss | DEXA: dual-energy X-ray absorptiometry, a low-dose body-composition scan; repeat on the same machine |
| Fasting glucose | 70–99 mg/dL (standard reference range) | Safety check: a sustained rise prompts stopping | 8–12 hour fast; pair with glycated hemoglobin |
| HbA1c | 4.0–5.6% (standard reference range) | Safety check: tracks average glucose over about 3 months | HbA1c: glycated hemoglobin; no fasting needed; less informative for courses under 12 weeks |
| IGF-1 | Age- and sex-specific laboratory range (standard reference range) | Safety check: a rise suggests a growth-hormone-like contaminant or stacked agent | Morning draw; interpret against the same laboratory’s age-adjusted range |
Qualitative markers:
- Injection-site redness, swelling or pain
- Headache or gastrointestinal upset
- Energy and exercise tolerance
- Joint pain and function, when used for osteoarthritis
- Hunger and satiety, expected to stay unchanged
Emerging Research
- Completed LAT8881 trials: Under the code LAT8881, three placebo-controlled trials found no pain benefit: neuropathic pain (pain from nerve damage) (NCT03865953, 53 participants), acute migraine (NCT04153409, 21) and lumbar radicular pain (leg pain from a pinched lower-spine nerve) (NCT05298306, 26); results are posted, not published.
- No ongoing trials: A ClinicalTrials.gov search on October 30, 2026 found no ongoing AOD-9604 or LAT8881 trial. A positive randomized trial of injected AOD-9604 would lift the weight-loss grade; a null result would close the question.
- Unpublished 24-week data: The sponsor’s negative 24-week trial is known only through secondary summaries (Misra 2013). Full publication would show dose-specific results and could weaken or modestly strengthen the case.
- Osteoarthritis translation: The cartilage benefit rests on one rabbit study (Kwon 2015); independent replication or a human joint trial could strengthen it, while failure would remove the main non-obesity rationale.
- Target identification: LanCL1 was identified as a binding target in nerve tissue (Spanswick 2026), but the receptor behind the fat effects remains unknown; beta-3 adrenergic involvement (Heffernan 2001) is unresolved.
- Safety surveillance: Reviews call for adverse-event reporting and product-quality monitoring for gray-market peptides (Hailu 2026); such data could confirm or dispel the cancer and contamination concerns.
- Regulatory re-evaluation: FDA’s July 2026 committee review of seven peptides did not include AOD-9604 (FDA PCAC July 23–24, 2026 meeting); a renewed nomination would trigger fresh FDA safety review.
Conclusion
AOD-9604 is a lab-made fragment of human growth hormone designed to keep the hormone’s fat-burning action without its effects on growth and blood sugar. For health-focused adults interested in body composition, the core question is whether it reduces body fat in people, and the human evidence leans against it. Animal studies were consistently favorable, and an early human study looked encouraging, but the developer’s larger and longer study did not show clear weight loss, and the program was abandoned. The way it is used today, by daily injection, has never been tested in people. Interest in joint cartilage repair rests on animal work alone.
The safety picture is reassuring in a narrow sense: in company studies of the oral form, side effects matched placebo except at the highest dose, and blood sugar and the hormone’s main growth signal did not change. Open questions remain, including an unexplained cluster of cancer diagnoses in one study, possible immune reactions to injected products, and the uncertain identity, purity and sterility of products sold online.
The evidence base is small and short, and almost all of it was produced or funded by the company developing the compound, a clear conflict of interest; its key negative result was never fully published. Regulators have raised safety concerns about its use in pharmacy-made medicines, and sports authorities ban it. Overall, the expected benefit is uncertain and probably small, while the main risks stem less from the molecule itself than from how it is obtained.